Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA. Dr...

USA. Trump Opioid Plan Writes in Favoritism to Single Company’s Addiction Medication The White House’s national strategy to combat the opioid crisis, unveiled last week, would expand a particular kind of addiction treatment ...

Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence. Saucier R, Wolfe D, Dasgupta N. Drug Saf. 2018 Mar 20. doi: 10.1007/s40264-018-0653-3. Abstract https://www.ncbi.nlm.nih.gov/pubmed/295...

Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. Bisaga A, Mannelli P, Sullivan MA, Vosburg SK, Compton P, Woody GE, Kosten TR. Am J Addict. 2018 Apr;27(3):177-187. doi: 10.1111/ajad.12...

Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, Oden NL, Lindblad R, S...

Extended-release injectable naltrexone for opioid use disorder: A systematic review. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K. Addiction. 2018 Feb 3. doi: 10.1111/add.14180. Abstract https://www.ncbi.nl...